46th week of 2018 patent applcation highlights part 9 |
Patent application number | Title | Published |
20180325808 | METHODS AND COMPOSITIONS FOR TREATMENT OF DISORDERS WITH FOLLISTATIN POLYPEPTIDES - The disclosure provides, in part, follistatin polypeptides that are suitable for use in local administration and methods for use. | 2018-11-15 |
20180325809 | LUBRICANT FORMULATIONS - A composition for lubricant formulations is disclosed. The composition may include hypochlorite, dimethicone, and an emulsifier for improvement of lubricity. Methods of making and using the lubricant formulations are also disclosed. | 2018-11-15 |
20180325810 | Formulations and Methods for Vaginal Delivery of Antiprogenstins - The subject matter of the present invention is pertinent to the field of vaginal delivery of pharmaceutically active agents. Embodiments of the instant invention disclose methods for treating a variety of progesterone related disorders by vaginal administration of a pullulan capsule and a fill formulation comprising one or more antiprogestins dispersed in a mixture of isopropyl palmitate or isopropyl myristate and a polyethylene glycol. | 2018-11-15 |
20180325811 | COMPOSITION FOR TREATING APOPLEXY THROUGH NASAL ADMINISTRATION - The present invention relates to a nasal administration composition for preventing or treating ischemic cerebrovascular disease, containing a Fas targeting peptide (FTP). When using the pharmaceutical composition or kit of the present invention, a drug can be effectively delivered to brain tissue and the ischemic cerebrovascular disease of a subject can be effectively prevented or treated. | 2018-11-15 |
20180325812 | OCULAR COMPOSITIONS - The invention provides an ocular composition comprising: 99 to 60% (w/w) of a photopolymerizable composition selected from the group of fragments or monomers consisting of polyalkylene glycol diacrylate and polyalkylene glycol dimethacrylate, wherein the photopolymerizable composition has a molecular weight in the range of 100 to 20,000 Dalton; a biodegradable polymer selected from the group consisting of aliphatic polyester-based polyurethanes, polylactides, polycaprolactones, polyorthoesters and mixtures, copolymers, and block copolymers thereof; a photoinitiator; and a therapeutic agent. The composition can be used to form an ocular implant and an in situ ocular implant. | 2018-11-15 |
20180325813 | ORAL SOLUTION OF ACE INHIBITORS - The present invention provides pharmaceutical oral solution composition of ACE inhibitor. The oral solution composition comprises of ACE inhibitor with 5-9 pH and other pharmaceutical excipients having improved stability and palatability. | 2018-11-15 |
20180325814 | CONFECTIONERY FOR ORAL CARE APPLICATIONS - The present invention is directed to a confectionery capable of imparting oral care benefits to an end-user, the confectionery containing: a first sweetener; an optional second sweetener, a flavorant and optionally a functional active ingredient for promoting tooth mineralization, wherein the confectionery is substantially sugar-free. The present invention is also directed to a method of imparting oral care benefits to a consumer involving inserting the above-described confectionery into a consumer's mouth and allowing the confectionery to dissolve in the consumer's mouth over a prolonged period of time. | 2018-11-15 |
20180325815 | PROCESS FOR PREPARING A DRY POWDER FORMULATION COMPRISING AN ANTICHOLINERGIC, A CORTICOSTEROID AND A BETA-ADRENERGIC - A process for preparing a dry powder formulation for inhalation comprising a combination of an anti-cholinergic, a long-acting beta | 2018-11-15 |
20180325816 | PROCESS FOR PREPARING A DRY POWDER FORMULATION COMPRISING AN ANTICHOLINERGIC, A CORTICOSTEROID AND A BETA-ADRENERGIC - A process for preparing a dry powder formulation for inhalation comprising a combination of an anti-cholinergic, a long-acting beta | 2018-11-15 |
20180325817 | AEROSILIZATION OF STEM CELLS OR STEM CELL DERIVATIVES FOR PULMONARY DELIVERY - A treatment system delivers a breathing gas and frozen stem cells or other biologic particles (FBP) to a bronchus of a lung of a patient in order to treat lung and other conditions. The breathing gas and the FBP are usually delivered through separate lumens. The FBP may be delivered concurrently with other frozen particles, such as frozen saline particles (FSP). The FBP/FSP will remain frozen at all times from preparation to delivery, and will thaw only after they are released into the lung. | 2018-11-15 |
20180325818 | UNIT DOSES, AEROSOLS, KITS, AND METHODS FOR TREATING HEART CONDITIONS BY PULMONARY ADMINISTRATION - Methods of treating a heart condition include administering by inhalation an effective amount of at least one antiarrhythmic pharmaceutical agent to a patient in need thereof. Nebulized drug product and kits are also contemplated. | 2018-11-15 |
20180325819 | GEL FORMULATIONS FOR LOCAL DRUG RELEASE - The present invention relates to a composition comprising non-water soluble carbohydrates, wherein at least 50% of the non-water soluble carbohydrates are carbohydrates selected from derivatives of lactose, maltose, trehalose, raffinose, glucosamine, galactosamine, lactosamine, or derivatives of disaccharides with at least two pyranose saccharide units, trisaccharides, tetrasaccharides, or mixtures thereof, and wherein the composition is a liquid before administration into the human or animal body and increases in viscosity by more than 1,000 centipoise (cP) after administration, for use as a medicament. | 2018-11-15 |
20180325820 | BIOCOMPATIBLE WATER-SOLUBLE POLYMERS INCLUDING SULFOXIDE FUNCTIONALITY - A biocompatible, water-soluble polymer includes segments formed via an atom transfer radical polymerization and including sulfoxide functionality. The segments including sulfoxide functionality have a dispersity less than or equal to 1.75 | 2018-11-15 |
20180325821 | NANOPARTICLE COMPOSITIONS FOR GENERATION OF REGULATORY T CELLS AND TREATMENT OF AUTOIMMUNE DISEASES AND OTHER CHRONIC INFLAMMATORY CONDITIONS - The present invention relates to nanoparticles for the targeted delivery of antigen to liver cells, in particular, liver sinusoidal endothelial cells (LSEC) and/or Kupffer cells, and for the in vivo generation of regulatory T cells, notably CD4+CD25+FOXP3+ regulatory T cells (Treg). The invention provides pharmaceutical compositions and methods for the prevention and treatment of autoimmune diseases, allergies or other chronic inflammatory conditions, and for generation of regulatory T cells. The nanoparticles used in the invention comprise a) a micelle comprising an amphiphilic polymer rendering the nanoparticle water-soluble, and b) a peptide comprising at least one T cell epitope associated with the outside of the micelle. The micelle may or may not comprise a solid hydrophobic core. | 2018-11-15 |
20180325822 | BIOCHARS FOR USE WITH ANIMALS - Biochars and methods for treating biochars are provided that are useful in various applications, including, but not limited to, applications related to the raising, care, maintenance, disease prevention, disease treatment and odor control of animals. | 2018-11-15 |
20180325823 | COMPACTED POWDER - The present invention is directed towards a compacted powder shaped to comprise: a) a substantially annular girdle having opposing circumferential edges, the girdle having a diameter (x); and b) a dome protruding from each of the opposing circumferential edges of the girdle, wherein the height of each dome (hd) from the circumferential edge is, individually, about 0.18x to about 0.28x. | 2018-11-15 |
20180325824 | METHOD FOR ACCELERATING THE SUGAR-COATING FORMATION OF SUGAR ALCOHOL COATING WITH CALCIUM LACTATE | 2018-11-15 |
20180325825 | GEMCABENE COMBINATIONS FOR THE TREATMENT OF CARDIOVASCULAR DISEASE - The present invention provides pharmaceutical compositions formulated to include a statin and gemcabene, wherein the composition is useful for treating, preventing, or reducing the symptoms of cardiovascular and metabolic indications that involve elevate levels of LDL cholesterol, triglycerides, or both. | 2018-11-15 |
20180325826 | CONTROLLED-RELEASE FORMULATION - The present invention relates to oral controlled-release formulations of 5-(pyridinyl)-2(1H)-pyridinone compounds and their use in the treatment of a subject with heart failure, a stage, class or manifestation of heart failure, or at risk of developing or exhibiting symptoms of heart failure. The formulations of the invention release the compounds in the range of between 0.1 μg/kg body weight/minute and 20 μg/kg body weight/minute. | 2018-11-15 |
20180325827 | DELIVERY SYSTEM - A delivery vehicle with a core surrounded by a digestible polymer shell having a melting and/or softening point above the body temperature of an animal or human, and where the core has a lipid and/or lipophilic active ingredient dispersed in a continuous polymer matrix. The delivery vehicle can be used to release lipid and/or lipophilic active ingredients, such as pharmaceuticals, nutraceuticals, supplements, traditional/herbal medicine, or combinations thereof, after a predetermined lag time following ingestion. | 2018-11-15 |
20180325828 | Device and Method for Granulating, Agglomerating, Pelletising, Drying and/or Coating - Provided is a device for granulating, agglomerating, pelletising, drying and/or coating, the device including a swirl chamber, a distribution chamber, wherein the swirl chamber is separated from the distribution chamber by a base and wherein a powder to be granulated or a powder mixture to be granulated is presented in the swirl chamber, the device further including at least one agitator for thoroughly mixing the powder to be granulated or the powder mixture to be granulated and at least one addition device for a liquid, wherein the base is designed in several parts and at least one base part is horizontally and/or vertically displaceable, with the result that that the base becomes a distributor plate. Also provided is a method for granulating, agglomerating, pelletising, drying and/or coating using such a device and a base suitable for use as a distributor plate in a convective drying apparatus. | 2018-11-15 |
20180325829 | MILLICAPSULE FORMULATIONS COMPRISING POLYUNSATURATED FREE FATTY ACIDS - Capsular dosage forms containing polyunsaturated fatty acid (PUFA) compositions are provided herein. In certain embodiments, unit dosage forms comprising a plurality of millicapsules containing a PUFA composition therein are provided as well as their methods of use and manufacture. In certain embodiments, capsular dosage forms are provided herein that include a unit dosage form comprising a plurality of millicapsules containing a polyunsaturated free fatty acid substantially in free acid form. In some embodiments, the PUFA composition is Epanova®. | 2018-11-15 |
20180325830 | COATED BIOLOGICAL COMPOSITION - A coated biological composition has a mixture of biologic material and a volume of a liquid protectant. The mixture of biologic material has non-whole cellular components or whole cells or combinations of the non-whole cellular components and whole cells, wherein the mixture is compatible with biologic function. The volume of a liquid protectant is intermixed with the mixture of biologic material, wherein the liquid protectant forms a coating externally enveloping each of the non-whole cellular components, if any, and each of the whole cells, if any, of the mixture of biologic material, to form the coated biological composition. The coated biological composition is frozen and thereafter thawed and then frozen a second time for storage or frozen at least once and thawed and stored under refrigeration above freezing, or frozen and thawed and then concentrated by drying, or while frozen without thawing lyophilized for ambient or room temperature storage. | 2018-11-15 |
20180325831 | NANO COMPLEX MATERIAL, DRUG CARRIER COMPRISING SAME, CONTRAST AGENT COMPRISING SAME, AND METHOD FOR PREPARING NANO COMPLEX MATERIAL - The present disclosure relates to a nano complex material, a drug carrier including the same, a contract agent including the same, and a method for preparing the nano complex material, and the nano complex material of the present disclosure consists of a support and ionic particles and thus can exhibit excellent light absorbance, magnetic absorbance, storage stability, functionality as a contrast agent, and drug delivery performance, as well as low cytotoxicity. | 2018-11-15 |
20180325832 | EDDS CHELATED NANOCERIA WITH CATALASE-LIKE ACTIVITY - A process for making nanoparticles of biocompatible materials is described, wherein an aqueous reaction mixture comprising cerous ion, ethylenediaminedisuccinic acid, an oxidant, water, and optionally citric acid, is provided along with temperature conditions to directly form within the reaction mixture, a stable dispersion of cerium oxide nanoparticles. Biocompatible, nanoparticles comprised of cerium oxide, ethylenediaminedisuccinic acid, and optionally citric acid, are described. An increase in catalase-like enzyme activity is demonstrated by cerium oxide nanoparticles prepared with citric acid and ethylenediaminedisuccinic acid. | 2018-11-15 |
20180325833 | NANOPARTICLES BASED ON OPTIONALLY ALKOXYLATED POLY(ALKYL CYANOACRYLATES) HAVING A DEFINED DEGREE OF POLYMERIZATION - The present invention relates to nanoparticles based on optionally alkoxylated poly(alkyl cyanoacrylates) having a defined molecular mass and dispersity, a method for preparing such nanoparticles, compositions comprising such nanoparticles and medical uses thereof. The invention further relates to the use of optionally alkoxylated poly(alkyl cyanoacrylates) having a defined molecular mass and dispersity for preparing nanoparticles as well as to a method for preparing such polymers. | 2018-11-15 |
20180325834 | COMPOSITIONS COMPRISING ELECTROHYDRODYNAMICALLY OBTAINED FIBRES FOR ADMINISTRATION OF SPECIFIC DOSAGES OF AN ACTIVE SUBSTANCE TO SKIN OR MUCOSA - The present invention relates to electrospun fibers comprising
| 2018-11-15 |
20180325835 | MODIFIED TRANSDERMAL DELIVERY PATCH WITH MULTIPLE ABSORBENT PADS - The invention is modified transdermal patch, which contains two or more absorbent pads placed atop one another within the drag reservoir of the patch, enabling the patch to (1) hold a greater quantity of the drag, (2) extend the useful life of the patch, (3) enhance the quantity of the dose which can be released from the patch, by either passive of active methods of drag release. | 2018-11-15 |
20180325836 | ULTRASONIC TRANSDUCERS SUITABLE FOR ULTRASONIC DRUG DELIVERY VIA A SYSTEM, WHICH IS PORTABLE AND WEARABLE BY THE PATIENT - The invention is a device for transmitting acoustical energy between an ultrasonic generator, through a medicine-containing patch, and into the exterior surface of the skin of a patient, typically known as an ultrasonic transducer. The ultrasonic transducer emits a sonic transmission of variable intensity and frequency for the purpose of enhancing the absorption through the patient's skin of pharmaceutical compounds stored within a transdermal patch or other medication holding device. The transducers are designed to accommodate an ultrasonic drug delivery system, which is worn by the patient. | 2018-11-15 |
20180325837 | Base Composition for Tape Agent - The present invention provides a composition for a non-aqueous patch preparation having an excellent adhesibility which can sustainedly release a drug. The patch preparation of the present invention can improve the adhesibility thereof as well as the release property of a drug by the addition of powder ingredient (e.g. a filler). As a result, the long-time sustention of the adhesibility of patch preparations can achieve the improvement of the transdermal absorbability and the sustained release of a drug. By the use of a composition for a patch preparation comprising this powder ingredient, a drug, regardless of the type of a drug is dissolved in an organic solvent or an ionic liquid to prepare a drug solution comprising the organic solvent, the drug solution is incorporated into the non-aqueous patch preparation of the present invention, and thereby a preparation with the improved transdermal-absorbability and sustained release can prepared. | 2018-11-15 |
20180325838 | TRANSDERMAL ADHESIVE COMPOSITIONS, DEVICES, AND METHODS - A stable transdermal adhesive composition comprising: an adhesive comprising a washed polymerization reaction product of at least two ethylenically unsaturated monomers; and at least one pharmaceutically active compound which is susceptible to oxidative degradation; wherein the at least two ethylenically unsaturated monomers, if present in the adhesive as unreacted monomers, are present at a level of less than 200 ppm of total unreacted monomer, based upon the total weight of the adhesive, methods of making the composition, a transdermal drug delivery device using the composition, methods of making the device, and methods of delivery the pharmaceutically active compound are provided. | 2018-11-15 |
20180325840 | COMPOSITIONS AND METHODS FOR PREVENTING OR TREATING FATTY PANCREAS OR AMELIORATING PANCREAS DISEASES CAUSED BY FATTY PANCREAS, DIABETES MELLITUS OR OTHER RELATED DISORDERS - The present invention relates to a composition and method for preventing or treating fatty pancreas, or ameliorating a pancreas disease caused by fatty pancreas, diabetes mellitus or other related disorders. | 2018-11-15 |
20180325841 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING ALZHEIMER'S DISEASE - The present disclosure relates to a use of a phloroglucinol-based compound and its salt for preventing and treating Alzheimer's disease. The pharmaceutical composition for preventing or treating Alzheimer's disease of the present disclosure fundamentally suppresses the cause of β-amyloid formation, thereby exerting a remarkable effect of allowing ultimate treatment of Alzheimer's disease. The present disclosure provides the use of the single substance, which has been isolated from | 2018-11-15 |
20180325842 | Mixture of stabilised biologically available curcumin for orodispersible formulations, formulations of biologically available curcumin, and an orodispersible tablet with biologically available curcumin, and its application - Orodispersible tablet with biologically available curcumin containing particles of extract of rhizome of plant | 2018-11-15 |
20180325843 | PHYTONADIONE COMPOSITIONS AND RELATED METHODS - Stable Phytonadione compositions for parenteral administration are provided which comprise (E) isomer of phytonadione at or greater than 97% w/w as the active ingredient, and is substantially free of (Z) isomer. Said compositions are stable, sterile, and particulate-free. Further, said compositions reduce or avoid allergic reactions to benzyl alcohol and polysorbate. In some aspects, the compositions are free or substantially free of benzyl alcohol and/or reduced amounts of polysorbate. Methods of manufacture and methods of administration also provided. | 2018-11-15 |
20180325844 | PHARMACOLOGICAL PROPHYLACTICS AGAINST STRESS-INDUCED AFFECTIVE DISORDERS AND THEIR ASSOCIATED SYMPTOMS - Methods for prophylactically treating a stress-induced affective disorder or stress-induced psychopathology in a subject are provided. Also provided are methods for inducing and/or enhancing stress resilience in a subject. In certain embodiments, an effective amount, of an antagonist of the glutamate N-methyl-D-aspartate (NMDA) receptor, such as ketamine, or a pharmaceutically acceptable salt or derivative thereof, is administered to a subject prior to a stressor. | 2018-11-15 |
20180325845 | AMINONAPHTHOQUINONE COMPOUNDS FOR TREATMENT AND/OR PREVENTION OF FIBROSIS DISEASES - The invention relates to the use of a compound of Formula (I) as described herein and its effective dose in the prevention and/or treatment of fibrosis diseases. The compound can effectively prevent and/or treat a fibrosis disease without cytotoxicity or genotoxicity. | 2018-11-15 |
20180325847 | METHODS OF TREATING LIVER FIBROSIS BY ADMINISTERING 3-BROMOPYRUVATE - Methods for treating or preventing liver fibrosis in a subject by administering to the subject a therapeutically effective amount of 3-bromopyruvate (3-BrPA) are provided. In addition, methods for promoting the reversal of an activated hepatic stellate cell (HSC) to an inactivated HSC by contacting the activated HSC with at least one 3-bromopyruvate (3-BrPA) molecule are also provided. | 2018-11-15 |
20180325848 | ORAL COMPOSITION - The present invention relates to an oral composition showing increased adsorption performance of an oil-soluble medicinal ingredient such as glycyrrhetinic acid and tocopherol to the gums and oral mucosa. The invention relates to an oral composition comprising the following ingredients (A), (B), (C), and (D): (A) 0.01 mass % or more and 2.5 mass % or less of one or more oil-soluble medicinal ingredients selected from the group consisting of glycyrrhetinic acid, tocopherol, and a tocopherol derivative; (B) 4 mass % or more and 30 mass % or less of a higher alcohol having 12 or more and 22 or less carbon atoms comprising (b1) cetanol and (b2) stearyl alcohol; (C) 0.1 mass % or more and 10 mass % or less of a surfactant including one or more selected from the group comprising of (c1) a nonionic surfactant selected from the group consisting of sorbitan fatty acid ester and polyoxyethylene sorbitan fatty acid ester, and (c2) an anionic surfactant being a fatty acid having 12 or more and 22 or less carbon atoms or a salt thereof; and (D) water, wherein a mass ratio of the content of (E) an oil agent other than ingredients (A), (B), and (C) and a flavoring agent to the content of ingredient (B), ((E)/(B)), is less than 1; and the content of (F) an abrasive powder comprising a polyvalent metal is 5 mass % or less. | 2018-11-15 |
20180325849 | GLYCOLIC ACID PROTECTS AGAINST ISCHEMIC INSULTS - The present invention relates to glycolic acid or a pharmaceutically acceptable salt or ester thereof for use in the treatment or prevention of ischemic damage. In a preferred embodiment the present invention relates to a method for decreasing cell death caused by an ischemic insult comprising contacting glycolic acid or a pharmaceutically acceptable salt or ester thereof with hypoxic tissue, in particular cortical neurons or myocardial tissue. | 2018-11-15 |
20180325850 | VALPROIC ACID FOR TREATMENT OF MYOCARDIAL ISCHEMIA - Provided herein are pharmaceutical compositions comprising valproic acid and methods of use thereof for the treatment and/or prevention of myocardial ischemia and/or infarction. | 2018-11-15 |
20180325851 | Transdermally-Delivered Combination Drug Therapy for Pain - The invention provides a topical formulation for treating pain comprising a nonsteroidal anti-inflammatory agent or a Cox-2 inhibitor and a gabapentin family member. | 2018-11-15 |
20180325852 | ALDITOL-FREE, STORAGE-STABLE THYROID HORMONE ACTIVE DRUG FORMULATIONS AND METHODS FOR THEIR PRODUCTION - Embodiments of the present invention provide pharmaceutical compositions in unit dosage form that comprise a therapeutically effective amount of levothyroxine sodium; an antioxidant in an amount sufficient to stabilize the levothyroxine sodium against oxidation; an amount of one or more of a monosaccharide, a disaccharide, and an oligosaccharide sufficient to stabilize the levothyroxine sodium; and two or more of a filler, a binder, and a lubricant. Such compositions are free of added alditol and are storage stable | 2018-11-15 |
20180325853 | BENZOQUINONE DERIVATIVE E3330 IN COMBINATION WITH CHEMOTHERAPEUTIC AGENTS FOR THE TREATMENT OF COLON CANCER - Disclosed are novel methods for the therapeutic treatment of cancer and angiogenesis. The enzyme Ape1/Ref-1, via its redox function, enhances the DNA binding activity of transcription factors that are associated with the progression of cancer. The present invention describes the use of agents to selectively inhibit the redox function of Ape1/Ref-1 and thereby reduce tumor cell growth, survival, migration and metastasis. In addition, Ape1/Ref-1 inhibitory activity is shown to augment the therapeutic effects of other therapeutics and protect normal cells against toxicity. Further, Ape1/Ref-1 inhibition is shown to decrease angiogenesis, for use in the treatment of cancer as well other pathologic conditions of which altered angiogenesis is a component. | 2018-11-15 |
20180325854 | USE OF PROTEASOME INHIBITORS TO TREAT OCULAR DISORDERS - Hydrocinnamate compounds that exhibit proteasome modulation activity, and in particular, proteasome inhibitory activity, can be used to topically or systemically treat ocular disorders associated with proteasome activity. The hydrocinnamate compounds can be applied to the eye, in any of a variety of ocular formulations, to treat ocular disorders, such as ocular rosacea, diabetic retinopathy, macular degeneration, and dry eye. The hydrocinnamate compounds can also be administered systemically to treat ocular disorders. | 2018-11-15 |
20180325855 | CONTROLLED RELEASE PHARMACEUTICAL COMPOSITIONS COMPRISING A FUMARIC ACID ESTER - The present invention relates to controlled release pharmaceutical compositions comprising fumaric acid ester(s) as active substance(s). The compositions are suitable for use in the treatment of e.g. psoriasis or other hyperproliferative, inflammatory or autoimmune disorders and are designated to release the fumaric acid ester in a controlled manner so that local high concentrations of the active substance within the gastrointestinal tract upon oral administration can be avoided and, thereby, enabling a reduction in gastro-intestinal related side-effects. | 2018-11-15 |
20180325856 | HALOGENATED ESTERS OF CYCLOPROPANATED UNSATURATED FATTY ACIDS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES - The present disclosure describes novel PKC-ε activators chosen from halogenated esters of unsaturated fatty acids and derivatives thereof, including halogenated esters of both polyunsaturated and monounsaturated fatty acids and derivatives thereof. The disclosure further relates to compositions, kits, and methods for treatment using the halogenated esters. | 2018-11-15 |
20180325857 | METHOD FOR TREATING HEMOLYTIC UREMIC SYNDROME - The present invention provides methods for treating, controlling or mitigating hemolytic uremic syndrome (HUS), comprising administering a monoacetyldiacylglycerol compound to a patient in need thereof, as well as compositions useful therefor. | 2018-11-15 |
20180325858 | METHODS OF TREATING UROLOGICAL DISORDERS USING SARMs - The present invention is directed to methods of treating, preventing, suppressing and/or inhibiting urological disorders such as urinary incontinence including stress urinary incontinence, urge urinary incontinence, mixed incontinence, and pelvic floor disorders by administering a SARM compound of the invention. | 2018-11-15 |
20180325859 | COMPOSITIONS COMPRISING A COMPOUND FROM THE FAMILY OF AVERMECTINS AND AN AGONIST COMPOUND FOR AT LEAST ONE OF THE RETINOIC ACID RECEPTORS FOR TREATING ACNE - Compositions including a compound of the family of avermectins, preferably ivermectin, and an agonist compound for at least one of the retinoic acid receptors are described. The compositions are in particular used in the treatment of acne. | 2018-11-15 |
20180325860 | Stable Analogs of CYP450 Lipid Metabolites and Inhibitors of Soluble Epoxide Hydrolase - This disclosure relates to methods of reducing inflammation, angiogenesis, vascular leakage and neovascularization by administering to a subject in need thereof one or more stable analogs of CYP450 lipid metabolites (e.g., eicosanoids) and one or more inhibitors of a soluble epoxide hydrolase (sEH). This disclosure also relates to methods of treating disorders associated with inflammation, angiogenesis, vascular leakage and neovascularization by administering to a subject in need thereof one or more stable analogs of CYP450 lipid metabolites (e.g., eicosanoids) and one or more inhibitors of a soluble epoxide hydrolase (sEH). This disclosure further relates to pharmaceutical compositions and kits comprising at least one stable analog of CYP450 lipid metabolites (e.g., eicosanoids) and at least one inhibitor of a soluble epoxide hydrolase (sEH). | 2018-11-15 |
20180325861 | NOVEL CANNABINOID FORMULATIONS - Provided are formulations and methods for improving oral bioavailability of cannabinoid compositions. | 2018-11-15 |
20180325862 | METHODS FOR TREATING ALZHEIMER?S DISEASE AND RELATED DISORDERS - The invention is directed to a method of treating Alzheimer's Disease by administering to a subject in need thereof a therapeutically effective amount of cromolyn and optionally ibuprofen. The cromolyn may be in the form of cromolyn sodium and administered by inhalation. | 2018-11-15 |
20180325863 | ANTIMICROBIAL COMPOSITIONS FOR CLOSTRIDIUM DIFFICILE - infects and kills 30,000-40,000 people a year in the United States. Provided herein are methods to inhibit growth and reduce the spread of | 2018-11-15 |
20180325864 | COMPOUNDS AND METHODS FOR TREATING AUTISM SPECTRUM DISORDERS - The present invention relates to a compound of the following formula (I): | 2018-11-15 |
20180325865 | Composition, Method Of Manufacture, And Use Of Site-Specific Delivery Of Bruceolides For Treatment Of Cancer And Other Diseases - Disclosed are bruceolides for the treatment of cancer, and other diseases, selectively targeting unwanted cells. The disclosed bruceolides may include a site specific cleavable moiety inhibiting the chemotoxic activity until cleaved, i.e., removed, within and/or near a cancer to be treated. As to facilitate selective delivery to cancer tumors, the disclosed bruceolides may be loaded into, attached to or otherwise carried by nanoparticles. | 2018-11-15 |
20180325866 | USE OF NK-1 RECEPTOR ANTAGONISTS IN PRURITUS - The invention relates to methods for treating pruritus with NK-1 receptor antagonists such as serlopitant. The invention further relates to pharmaceutical compositions comprising NK-1 receptor antagonists such as serlopitant. In addition, the invention encompasses treatment of a pruritus-associated condition with serlopitant and an additional antipruritic agent, and the use of serlopitant as a sleep aid, optionally in combination with an additional sleep-aiding agent. | 2018-11-15 |
20180325867 | USE OF NK-1 RECEPTOR ANTAGONIST SERLOPITANT IN PRURITUS - The invention relates to methods for treating pruritus with NK-1 receptor antagonists such as serlopitant. The invention further relates to pharmaceutical compositions comprising NK-1 receptor antagonists such as serlopitant. In addition, the invention encompasses treatment of a pruritus-associated condition with serlopitant and an additional antipruritic agent, and the use of serlopitant as a sleep aid, optionally in combination with an additional sleep-aiding agent. | 2018-11-15 |
20180325868 | SELECTIVE OCTAHYDRO-CYCLOPENTA[C]PYRROLE NEGATIVE MODULATORS OF NR2B - Compounds that selectively negatively modulate NMDA receptors containing an NR1/NR2B subunit, pharmaceutical compositions comprising the compounds, and methods of treating a disease using the compounds are disclosed. | 2018-11-15 |
20180325869 | TARGETING OF THE FORMYL-PEPTIDE RECEPTOR 2/LIPOXIN A4 RECEPTOR (FPR2/ALX) FOR TREATMENT OF HEART DISEASE - The disclosure generally relates to a therapeutic approach based on the stimulation of resolution of inflammation by the Formyl-Peptide Receptor 2/Lipoxin A | 2018-11-15 |
20180325871 | ANTIMITOTIC AMIDES FOR THE TREATMENT OF CANCER AND PROLIFERATIVE DISORDERS - Novel, antimitotic heteroaryl amides and pharmaceutically acceptable salts of Formula I where Ar, R | 2018-11-15 |
20180325872 | COMPOUNDS FOR TREATMENT OF CANCER - The present invention relates to pharmaceutical compositions for treating cancer comprising BRAF inhibitors, (e.g. vemurafenib) and/or MEK inhibitor, (e.g. trametinib, RO5068760), in combination with anti-tubulin compounds of the invention or other known tubulin inhibitors, and using such compositions for treating cancer such as melanoma, drug-resistant cancer, and cancer metastasis. | 2018-11-15 |
20180325873 | PYRAZOLYLAMINOBENZIMIDAZOLE DERIVATIVES AS JAK INHIBITORS - The present invention provides compounds of the formula below (I′): where R, and R1-R3 are as described herein, methods of treating patients for certain types of autoimmune diseases and cancer, and processes for preparing the compounds. | 2018-11-15 |
20180325874 | [1,2,4]TRIAZOLO[1,5-A]PYRIDINYL SUBSTITUTED INDOLE COMPOUNDS - Disclosed are compounds of Formula (I) | 2018-11-15 |
20180325875 | COMBINATION THERAPY FOR PULMONARY HYPERTENSION - The present invention provides compositions and methods for the treatment of pulmonary hypertension using combination therapy. The combination therapy comprises a compound that increases BMPR2 signaling (BMPR2 activator) in combination with at least one other agent for the treatment of pulmonary hypertension. In certain aspects, the BMPR2 activator can be tacrolimus or a pharmaceutically acceptable solvate, salt, or prodrug thereof. | 2018-11-15 |
20180325876 | Sibiriline Derivatives For Use For Preventing And/Or Treating Disorders Associated With Cellular Necroptosis - The present invention relates to a compound of the following general formula (I) or a pharmaceutically acceptable salt and/or solvate thereof, for use as inhibitor of cellular necroptosis. The present invention also relates to a pharmaceutical composition comprising a compound of general formula (I), or a pharmaceutically acceptable salt and/or solvate thereof, for use for preventing and/or treating disorders associated with cellular necroptosis. The present invention also encompasses the use of a compound of the general formula (I) for organs preservation. | 2018-11-15 |
20180325877 | Use of Maleimide Derivatives for Preventing and Treating Cancer - The present invention is related to a compound of formula (I): | 2018-11-15 |
20180325878 | N-BIARYLAMIDES - The invention relates to N-biarylamides, methods for production and use thereof for the production of medicaments for the treatment and/or prophylaxis of diseases and for improvement in cognition, concentration power, learning power and/or memory. | 2018-11-15 |
20180325879 | Antibacterial compositions - Pharmaceutical compositions comprising S-(−)-9-fluoro-6,7-dihydro-8-(4-hydroxypiperidin-1-yl)-5-methyl-1-oxo-1H,5H-benzo[i,j]quinolizine-2-carboxylic acid L-arginine salt, and their use in treatment, control or prevention of bacterial infections is disclosed. | 2018-11-15 |
20180325880 | PHARMACEUTICAL COMPOSITIONS OF THERAPEUTICALLY ACTIVE COMPOUNDS - Provided are compounds and pharmaceutical compositions useful for treating cancer and methods of treating cancer comprising administering to a subject in need thereof a compound or pharmaceutical composition described herein. | 2018-11-15 |
20180325881 | Methods for Treatment of Fabry Disease - Provided are in vitro and in vivo methods for determining whether a patient with Fabry disease will respond to treatment with a specific pharmacological chaperone. | 2018-11-15 |
20180325882 | STABLE NIMODIPINE PARENTERAL FORMULATION - A nimodipine injection concentrate and diluted formulation comprises nimodipine (base or salt), an effective amount of a hydrophilic surfactant, and a pharmaceutically acceptable carrier for injection which is an aqueous solution, an organic solvent, an oil, or a cyclodextrin, such that the nimodipine is substantially contained in a concentrated injection solution, suspension, emulsion or complex as a micelle or a colloidal particle or an inclusion complex and the formulation is stable and clear. In certain embodiments, the hydrophilic surfactant is polysorbate 80. | 2018-11-15 |
20180325883 | Use of 2-carboxamide cycloamino urea derivatives in the treatment of EGFR dependent diseases or diseases that have acquired resistance to agents that target EGFR family members - The use of compounds of formula (I) | 2018-11-15 |
20180325884 | METHODS AND DEVICES FOR THE TREATMENT OF OCULAR DISEASES IN HUMAN SUBJECTS - Methods and devices are provided for targeted non-surgical administration of a drug formulation to the suprachoroidal space (SCS) of the eye of a human subject for the treatment of a posterior ocular disorder or a choroidal malady. In one embodiment, the method comprises inserting a hollow microneedle into the eye at an insertion site and infusing a drug formulation through the inserted microneedle and into the suprachoroidal space of the eye, wherein the infused drug formulation flows within the suprachoroidal space away from the insertion site during the infusion. In one embodiment, the fluid drug formulation comprises drug nanoparticles or microparticles. | 2018-11-15 |
20180325885 | FORMULATIONS OF 4-AMINO-2-(2,6-DIOXOPIPERIDINE-3-YL)ISOINDOLINE-1,3-DIONE - Pharmaceutical compositions and single unit dosage forms of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione, or a pharmaceutically acceptable stereoisomer, prodrug, salt, solvate, hydrate, or clathrate, are provided herein. Also provided are methods of treating, managing, or preventing various disorders, such as cancer or an inflammatory disease. | 2018-11-15 |
20180325886 | STABLE NIMODIPINE PARENTERAL FORMULATION - A nimodipine injection concentrate and diluted formulation comprises nimodipine (base or salt), an effective amount of a hydrophilic surfactant, and a pharmaceutically acceptable carrier for injection which is an aqueous solution, an organic solvent, an oil, or a cyclodextrin, such that the nimodipine is substantially contained in a concentrated injection solution, suspension, emulsion or complex as a micelle or a colloidal particle or an inclusion complex and the formulation is stable and clear. In certain embodiments, the hydrophilic surfactant is polysorbate 80. | 2018-11-15 |
20180325887 | N-[2-(1-BENZYLPIPERIDIN-4-YL)ETHYL]-4-(PYRAZIN-2-YL)-PIPERAZINE-1-CARBOXAM- IDE DERIVATIVES AND RELATED COMPOUNDS AS MUSCARINIC RECEPTOR 4 (M4) ANTAGONISTS FOR TREATING NEUROLOGICAL DISEASES - Provided herein are small molecule compounds of the following formula (I): or a stereoisomer, tautomer, solvate, ester or pharmaceutically acceptable salt thereof, wherein A, B, C, L | 2018-11-15 |
20180325888 | Atropine Pharmaceutical Compositions - The inventive subject matter is directed to compositions and methods for sterile and storage stable low-dose atropine formulations with improved stability. Most preferably, the compositions presented herein are substantially preservative free and exhibit less than 0.35% tropic acid from degradation of atropine. Advantageously, contemplated formulations are also substantially free of preservatives. | 2018-11-15 |
20180325889 | IMMUNOREGULATORY AGENTS - Compounds that modulate the oxidoreductase enzyme indoleamine 2,3-dioxygenase, and compositions containing the compounds, are described herein. The use of such compounds and compositions for the treatment and/or prevention of a diverse array of diseases, disorders and conditions, including cancer- and immune-related disorders, that are mediated by indoleamine 2,3-dioxygenase is also provided. | 2018-11-15 |
20180325890 | METHODS AND PHARMACEUTICAL COMPOSTIONS FOR TREATING RHABDOMYOLYSIS - The present invention relates to methods and pharmaceutical compositions for treating rhabdomyolysis. | 2018-11-15 |
20180325891 | OCTAHYDRO AZADECALIN FORMULATIONS - Applicant provides formulations and pharmaceutical compositions containing glucocorticoid receptor modulators (GRMs) and suitable for treating diseases including Cushing's syndrome, prostate cancer, breast cancer, and other cancers, liver diseases, depression, dementia, stress disorders, and substance abuse disorders. The GRM may be a non-steroidal GRM, and may be an octahydro azadecalin GRM. In particular, the GRM may be CORT125281, which is: ((4aR,8aS)-1-(4-fluorophenyl)-6-((2-methyl-2H-1,2,3-triazol-4-yl)sulfonyl)-4,4a,5,6,7,8,8a,9-octahydro-1H-pyrazolo[3,4-g]isoquinolin-4a-yl)(4-(trifluoromethyl)pyridin-2-yl)methanone. Methods of treating diseases including Cushing's syndrome, liver diseases, cancers, and psychiatric disorders by administration of a GRM in such pharmaceutical compositions are also provided. | 2018-11-15 |
20180325892 | PHARMACEUTICAL COMPOSITIONS - Methods and compositions are provided which comprise effective amounts of an analgesic to treat a subject, including reducing or eliminating an adverse effect associated with the analgesic. | 2018-11-15 |
20180325893 | SUBACUTE ADMINISTRATION OF NMDA MODULATORS ALONE OR IN COMBINATION - This disclosure features combinations of NMDA modulators and atypical antipsychotics. The disclosure provides for example, methods of treating schizophrenia, bipolar disorder, and/or cognitive impairment disorder in a patient in need thereof, comprising administering e.g., rapastinel and an atypical antipsychotic. | 2018-11-15 |
20180325894 | COMBINATIONS COMPRISING BREXPIPRAZOLE OR A SALT THEREOF AND A SECOND DRUG FOR USE IN THE TREATMENT OF A CNS DISORDER - The present invention provides a medicament having a wider treatment spectrum, causing a fewer side effects and superior in tolerability and safety, as compared to known typical antipsychotic agents and atypical antipsychotic agents. The present invention related to a medicament containing (I) a compound which is 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one or a salt thereof, and (II) at least one drug selected form the group consisting of a mood stabilizer, a serotonin reuptake inhibitor, a norepinephrine reuptake inhibitor, a serotonin and norepinephrine reuptake inhibitor, a noradrenergic and specific serotonergic antidepressant, an antianxiety drug, a tricyclic antidepressant, a tetracycline antidepressant, an antipsychotic drug and an anti-ADHD drug, in combination | 2018-11-15 |
20180325895 | PHARMACEUTICAL COMPOSITION CONTAINING 2-{4-[N-(5,6-DIPHENYLPYRAZIN-2-YL)-N-ISOPROPYLAMINO]BUTYLOXY}-N-(METHYLSU- LFONYL)ACETAMIDE - A stabilized solid preparation containing 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsulfonyl)acetamide is provided, namely, a solid preparation containing 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsulfonyl)acetamide and D-mannitol having a specific surface area of 1.0 m | 2018-11-15 |
20180325896 | SYK INHIBITORS - The present disclosure relates to compounds that are Syk inhibitors and to their use in the treatment of various disease states, including cancer and inflammatory conditions. In particular embodiments, the structure of the compounds is given by Formula I: | 2018-11-15 |
20180325897 | CO-CRYSTALS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME - The present invention relates to compositions and co-crystals each comprising a compound of formula I having the structure: | 2018-11-15 |
20180325898 | DNA-PK INHIBITORS - The present invention relates to compounds useful as inhibitors of DNA-PK. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders. | 2018-11-15 |
20180325899 | IMIDAZOPYRIDAZINE COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHA RESPONSES - Compounds of formula I or a stereoisomer or pharmaceutically-acceptable salt thereof, are useful in the modulation of IL-12, IL-23 and/or IFNα, by acting on Tyk-2 to cause signal transduction inhibition. | 2018-11-15 |
20180325900 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 - The present invention relates generally to compositions and methods for treating cancer and neoplastic disease. Provided herein are substituted heterocyclic derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition of lysine specific demethylase-1. Furthermore, the subject compounds and compositions are useful for the treatment of cancer. | 2018-11-15 |
20180325901 | CHIRAL DIARYL MACROCYCLES AND USES THEREOF - This disclosure relates to the use of certain diaryl macrocycle compounds, specifically (7S13R)-11-fluoro-7,13-di-methyl-6,7,13,14-tetrahydro-1,15-ethenopyrazolo [4,3-f][1,4,8,10]benzoxatriazacyclotridecin-4(5H)-one in the treatment of disease in mammals. This disclosure also relates to compositions including such compounds, and to methods of using such compositions in the treatment of diseases in mammals, especially in humans. | 2018-11-15 |
20180325902 | COMPOSITIONS AND METHODS RELATING TO CANCER - Compositions and methods continue to be required for treatment of cancer. Compositions and methods according to aspects of the present invention relate to inhibition of a combination of kinases for treatment of cancer, specifically inhibition of both AKT and WEE1 kinases for treatment of cancer in a human subject. Synergistic effects of combination compositions and treatments including administration of an AKT inhibitor and a WEE1 inhibitor are unexpectedly found as described herein. | 2018-11-15 |
20180325903 | THERAPEUTIC METHODS AND COMPOSITIONS - The invention provides compositions and methods that are effective to improve NO production in vivo and/or to increase NO levels in blood. Such compositions and methods may be useful to improve the effects of PDE | 2018-11-15 |
20180325904 | ADMINISTRATION OF NEDD8-ACTIVATING ENZYME INHIBITOR AND CHEMOTHERAPEUTIC AGENTS - Disclosed are methods for the treatment of various solid tumors in patients in need of such treatment. The methods comprise administering to such a patient an NEDD8-activating enzyme (NAE) inhibitor such as ((1S,2S,4R)-4-(4-((1S)-2,3-dihydro-1H-inden-1-ylamino)-7H-pyrrolo[2,3-d]-pyrimidin-7-yl)-2-hydroxycyclopentyl)methyl sulfamate (MLN4924) or a pharmaceutically acceptable salt in combination with one or more chemotherapeutic agents. Also disclosed are medicaments for use in the treatment of various solid tumors. | 2018-11-15 |
20180325905 | SUSTAINED RELEASE SMALL MOLECULE DRUG FORMULATION - An injectable depot formulation includes a biocompatible polymer, an organic solvent combined with the biocompatible polymer to form a viscous gel, and a small molecule drug incorporated in the viscous gel such that the formulation exhibits an in vivo release profile having a C | 2018-11-15 |
20180325906 | THEOBROMINE COMPOSITIONS USEFUL FOR INCREASING FETAL WEIGHT GAIN AND ENHANCING BONE PROPERTIES - Compositions and methods for culturing cells with theobromine are provided, as well as cells derived thereby. Theobromine compositions for enhancing bone formation, increasing bone density, increasing interconnections of internal bone, increasing bone mass, treating cartilage and/or bone defects, increasing fetal birth weight, preventing tooth decay, remineralizing a tooth surface, treating dentine hypersensitivity, and application to a bone site to promote new bone growth at the site are also provided. | 2018-11-15 |
20180325907 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING CARDIOVASCULAR DISEASES - Provided herein is a pharmaceutical composition comprising two or more compounds, wherein each compound is independently a phosphodiesterase inhibitor, an adenosine receptor antagonist, a calcium channel blocker, a histamine H | 2018-11-15 |
20180325908 | METHODS AND COMPOSITIONS FOR TREATING PULMONARY HYPERTENSION - The present disclosure provides compositions and methods for treating pulmonary hypertension. The compositions and methods are based on administering a NO-releasing compound, such as nitrite, to a subject in need thereof in an amount sufficient to increase the level of circulating nitric oxide (NO), a potent vasodilator, thereby reducing the subject's blood pressure and increasing blood flow. | 2018-11-15 |
20180325909 | COMBINATION TREATMENT OF SPECIFIC FORMS OF EPILEPSY - Formulations for and methods of treatment of Dravet syndrome that avoid side effects are disclosed. The formulations comprise a 5-HT receptor agonists which does not agonize selected 5-HT receptor subtypes, and in particular does not agonize the receptor subtype 5-HT2B. Also disclosed are combinations of such 5-HT receptor agonists. Also disclosed are combinations of such 5-HT receptor agonists and SSRIs, SNRIs, and triptans for treating co-morbidities associated with Dravet syndrome. | 2018-11-15 |
20180325910 | 3-(1H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-B]PYRIDINE AND THERAPEUTIC USES THEREOF - Azaindazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present invention concerns the use of an azaindazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states. | 2018-11-15 |